Cote D Ivoire to India Pharmaceutical Import

The pharmaceutical trade corridor between Côte d'Ivoire and India has remained minimal from 2022 to 2026. In 2022, India imported pharmaceutical products worth $25 from Côte d'Ivoire, according to the United Nations COMTRADE database. This figure remained unchanged in subsequent years, indicating a stagnant trade relationship in this sector. The limited volume suggests that the pharmaceutical trade between the two nations has not experienced significant growth or development during this period.

Côte d'Ivoire's contribution to India's pharmaceutical imports is negligible, accounting for a minimal fraction of India's total pharmaceutical import value. The primary product imported from Côte d'Ivoire is plasma, with a total import value of $0 and a share of 0.0%. This indicates that Côte d'Ivoire does not play a significant role in supplying pharmaceutical products to India.

Between 2024 and 2026, there have been no notable developments in the pharmaceutical trade between Côte d'Ivoire and India. No new trade agreements, policy changes by the Central Drugs Standard Control Organisation (CDSCO), or regulatory harmonization efforts have been reported. The stagnant trade volume suggests a lack of significant policy or regulatory changes affecting this trade corridor during this period.

For pharmaceutical products to be imported into India, they must be registered with the CDSCO under Form 41. This registration serves as authorization for the importation of specific pharmaceutical products. Additionally, companies engaged in pharmaceutical import activities must obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT). The IEC is a prerequisite for customs clearance and facilitates international trade transactions. Importers are also required to submit an authorization letter from the manufacturer or marketing authorization holder (MAH) authorizing them to import specific pharmaceutical products on their behalf.

India requires that manufacturing sites comply with Good Manufacturing Practices (GMP) standards to ensure the quality and safety of pharmaceutical products. The CDSCO conducts inspections to verify compliance with these standards. Manufacturing sites must also obtain WHO prequalification, which is a prerequisite for exporting pharmaceutical products to India. This prequalification ensures that the manufacturing site meets international quality standards recognized by the World Health Organization.

Importers must obtain an import license (Form 10) issued by the CDSCO, which is mandatory for importing pharmaceutical products into India. The registration certificate under Form 41 serves as authorization for the importation of specific pharmaceutical products. A No Objection Certificate (NOC) from the manufacturer or marketing authorization holder (MAH) is required, authorizing the importer to import specific pharmaceutical products on their behalf. A test license may be required for certain products to ensure they meet Indian standards. Customs procedures involve submitting the necessary documentation to Indian customs authorities for clearance.

The pharmaceutical imports from Côte d'Ivoire to India are limited, with plasma being the only product imported, accounting for 100% of the import value. This suggests that there are no significant therapeutic areas or product types dominating India's pharmaceutical imports from Côte d'Ivoire.

Given the minimal volume of pharmaceutical imports from Côte d'Ivoire to India, there are no notable innovator drugs, novel formulations, or advanced therapies sourced from Côte d'Ivoire that are not manufactured domestically in India.

The negligible pharmaceutical imports from Côte d'Ivoire to India indicate that factors such as patent protection, technology gaps, quality requirements, or disease burden are not significant drivers for importing pharmaceutical products from Côte d'Ivoire.

India's import tariff structure for pharmaceutical formulations includes the Most Favored Nation (MFN) tariff rates, basic customs duty, Integrated Goods and Services Tax (IGST), and health cess. However, specific tariff rates and duties applicable to pharmaceutical imports from Côte d'Ivoire are not detailed in the available data. The minimal import volume suggests that these tariffs and duties have a limited impact on the trade between the two countries.

There is no evidence of a Free Trade Agreement (FTA) between India and Côte d'Ivoire, nor are there preferential duty rates or bilateral negotiations specifically affecting pharmaceutical imports. The stagnant trade volume indicates a lack of significant trade agreements or preferences in this sector.

India's patent regime, including Section 3(d), compulsory licensing, and price control measures by the National Pharmaceutical Pricing Authority (NPPA), applies to imported drugs. However, the minimal pharmaceutical imports from Côte d'Ivoire suggest that these intellectual property and price control mechanisms have limited relevance in this trade corridor.

The pharmaceutical trade between Côte d'Ivoire and India is minimal, with only one recorded shipment. Therefore, specific details regarding major sea and air routes, transit times, and route reliability are not available.

The primary export ports in Côte d'Ivoire include the Autonomous Port of Abidjan and the port of San-Pedro. In India, major import ports include Jawaharlal Nehru Port (Nhava Sheva), Mumbai Port, and Chennai Port. However, given the minimal pharmaceutical trade between the two countries, specific data on port infrastructure handling these shipments is limited.

For pharmaceutical imports, Indian customs procedures involve clearance by customs authorities, which includes verification of import documentation and compliance with regulatory requirements. The Central Drugs Standard Control Organisation (CDSCO) conducts testing to ensure that imported pharmaceutical products meet Indian standards. Cold chain management and Good Distribution Practice (GDP) compliance are critical for maintaining the quality of pharmaceutical products during transit. However, due to the minimal volume of pharmaceutical imports from Côte d'Ivoire, specific details on these logistics aspects are not extensively documented.

Despite being a major pharmaceutical manufacturer, India imports certain pharmaceutical products to meet specific needs, such as patented drugs, biologics, or products not manufactured domestically. However, the negligible pharmaceutical imports from Côte d'Ivoire suggest that India does not rely on Côte d'Ivoire for these products.

There is limited information available regarding major Côte d'Ivoire pharmaceutical companies supplying India. The minimal trade volume indicates that Côte d'Ivoire companies have limited presence or partnerships in the Indian pharmaceutical market.

India's Atmanirbhar Bharat initiative and the Production-Linked Incentive (PLI) scheme aim to boost domestic pharmaceutical manufacturing and reduce import dependency. Given the minimal pharmaceutical imports from Côte d'Ivoire, it is unlikely that these imports will grow significantly or be substituted by domestic production in the near future.

India imports pharmaceutical products from various countries, including the USA, EU, China, Switzerland, and Japan. Côte d'Ivoire's share in this import landscape is negligible compared to these other origins. The minimal trade volume suggests that Côte d'Ivoire does not compete significantly in supplying pharmaceutical products to India.

The limited pharmaceutical trade between Côte d'Ivoire and India indicates that Côte d'Ivoire's products do not possess significant competitive advantages in the Indian market, such as innovation, quality, patent protection, or brand reputation.

Indian manufacturers are continually developing alternatives to imported pharmaceutical products, including biosimilars, process patents, and expanding capacity through initiatives like the PLI scheme. The minimal pharmaceutical imports from Côte d'Ivoire suggest that domestic competition and threats in this sector are not significantly influenced by Côte d'Ivoire's pharmaceutical products.